New EASO guidance recommends semaglutide and tirzepatide as first-line treatments for obesity and its major complications

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, ...
The American Journal of Managed Care

Weight Loss Medications Show Promise in MASLD, MASH

Centrally acting agents like phentermine/topiramate and naltrexone/bupropion aid weight reduction but lack MASLD-specific data and carry potential risks such as hepatotoxicity, teratogenicity, or ...
Everyday Health on MSN

Can You Reverse MASH?

Metabolic-associated steatohepatitis (MASH) can cause liver damage, which can be stopped or reversed if it’s caught early. Learn more about the treatments that may help.
pharmaphorum

GLP-1s from Novo, Lilly 'should be first-line in obesity'

The European Association for the Study of Obesity (EASO) has called for GLP-1 agonists from Novo Nordisk and Eli Lilly to be ...
Science Daily

This new semaglutide dose helped nearly half of patients lose 20% body weight

The STEP UP trials revealed that a 7.2 mg dose of semaglutide led to greater weight loss than the currently approved 2.4 mg ...
The American Journal of Managed Care

EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy

Semaglutide and tirzepatide should be considered the first-choice pharmacologic treatments for individuals living with obesity and most related complications, according to a new framework from the ...

Viking Therapeutics: A Speculative Buy

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...
MyHorryNews

Loris City Council gives $10,000 to chamber of commerce

The Loris City Council provided funding to the Loris Chamber of Commerce to cover rent and also set the official ...